相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Taspoglutide, a novel human once-weekly analogue of glucagon-like peptide-1, improves glucose homeostasis and body weight in the Zucker diabetic fatty rat
E. Sebokova et al.
DIABETES OBESITY & METABOLISM (2010)
Taspoglutide, an Analog of Human Glucagon-Like Peptide-1 with Enhanced Stability and in Vivo Potency
Elena Sebokova et al.
ENDOCRINOLOGY (2010)
Treatment With the Human Once-Weekly Glucagon-Like Peptide-1 Analog Taspoglutide in Combination With Metformin Improves Glycemic Control and Lowers Body Weight in Patients With Type 2 Diabetes Inadequately Controlled With Metformin Alone A double-blind placebo-controlled study
Michael A. Nauck et al.
DIABETES CARE (2009)
Pharmacokinetic and pharmacodynamic properties of taspoglutide, a once-weekly, human GLP-1 analogue, after single-dose administration in patients with Type 2 diabetes
C. Kapitza et al.
DIABETIC MEDICINE (2009)
Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study
Arne Astrup et al.
LANCET (2009)
Medical Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy A consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes
David M. Nathan et al.
DIABETES CARE (2009)
Rosiglitazone no longer recommended
[Anonymous]
LANCET (2008)
The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes
Daniel J. Drucker et al.
LANCET (2006)
Biologic actions and therapeutic potential of the proglucagon-derived peptides
DJ Drucker
NATURE CLINICAL PRACTICE ENDOCRINOLOGY & METABOLISM (2005)
Glucagon-like peptide 1 and its derivatives in the treatment of diabetes
MA Nauck et al.
REGULATORY PEPTIDES (2005)
Effectiveness of progressive dose-escalation of exenatide (exendin-4) in reducing dose-limiting side effects in subjects with type 2 diabetes
MS Fineman et al.
DIABETES-METABOLISM RESEARCH AND REVIEWS (2004)
分享论文
